• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
【24h】

The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

机译：The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy. Copyright (C) 2016, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号